<DOC>
	<DOC>NCT00365001</DOC>
	<brief_summary>This 2 arm study will investigate the pharmacokinetics of simvastatin and methotrexate in combination with tocilizumab to assess any potential drug interactions. Patients will be randomized to receive either tocilizumab (10mg/kg iv infusion on day 8) + methotrexate (10-25mg po /week) or tocilizumab + methotrexate + simvastatin (40mg po on days 1, 15 and 43). Blood samples will be taken for analysis at intervals up to day 44. The anticipated time on study treatment is &lt;3 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>adult patients, 1875 years of age; rheumatoid arthritis for &gt;=6 months; methotrexate for &gt;=12 weeks prior to day 1 (stable at 1025mg/week for 8 weeks). history of, or current inflammatory joint disease or rheumatic autoimmune disease other than RA; concurrent treatment with any DMARD other than methotrexate; prior treatment with tocilizumab.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>